In patients failing two lines of TKI, dasatinib or nilotinib can be beneficial and safely administered as a third-line treatment especially in nations with restricted resources.

No abstract

Objective:In this study, we retrospectively analyzed the clinical outcome, treatment responses, infectious complications, and survival rates of 71 hairy cell leukemia (HCL) cases.Materials and Methods:Sixty-seven patients received a first-line treatment and 2-chlorodeoxyadenosine (cladribine-2-CdA) was administered in 31 cases, 19 patients received interferon-alpha (INF-α), splenectomy was performed in 16 cases, and rituximab was used in one.Results:Although the highest overall response rate (ORR) was observed in patients receiving 2-CdA upfront, ORRs were comparable in the 2-CdA, INF-α, and splenectomy subgroups. Relapse rates were significantly lower in patients who received first-line 2-CdA. The progression-free survival (PFS) rate with 2-CdA was significantly higher than in patients with INF-α and splenectomy, but we found similar overall survival rates with all three upfront treatment modalities. Infections including tuberculosis were a major problem.Conclusion:Although purine analogues have improved the ORRs and PFS, there is still much progress to make with regard to overall survival and relapsed/refractory disease in patients with HCL.

Objectives. The aim of this study was to evaluate clinical characteristics, prognostic factors, survival rates, and treatment modalities in patients with primary gastric lymphoma (PGL). Methods. We retrospectively reviewed and analyzed data from patients treated for PGL in our clinic from 1998 through 2010. Staging was performed using the Lugano Staging System. Overall and disease-free survival (OS and DFS) were calculated from the date of diagnosis. Results. We identified 79 patients. Thirty-seven patients (47%) were male. The median age at presentation was 57 (18–85) years. The median follow-up time was 41 (9–52) months. Thirty patients (38%) underwent surgery, 74 (92%) received chemotherapy, and 18 (23%) received radiotherapy. The five-year OS and DFS rates were 91.2% and 83.9%, respectively, in patients with stage I/II or IIE disease and 70.6% and 65.5%, respectively, in patients with stage IV disease (P = 0.02 for both rates). Treatment modality (surgical or conservative) had no impact on OS or DFS in early stages. In a multivariate analysis, poor performance status, advanced stage, and high LDH levels were significant bad prognostic factors for DFS, while advanced stage, poor performance status, and age > 60 years were significant bad prognostic factors for OS. Conclusion. Surgery provides no advantage for survival over conservative treatment; thus, conservative treatment modalities should be preferred initially at early stages of PGL.

Objective This study aims at developing a pipeline that provides the capability to include the catheter effect in the computational fluid dynamics (CFD) simulations of the cardiovascular system and other human vascular flows carried out with the open-source software SimVascular. This tool is particularly useful for CFD simulation of interventional radiology procedures such as tumor embolization where estimation of a therapeutic agent distribution is of interest. Results A pipeline is developed that generates boundary condition files which can be used in SimVascular CFD simulations. The boundary condition files are modified such that they simulate the effect of catheter presence on the flow field downstream of the inlet. Using this pipeline, the catheter flow, velocity profile, radius, wall thickness, and deviation from the vessel center can be defined. Since our method relies on the manipulation of the boundary condition that is imposed on the inlet, it is sensitive to the mesh density. The finer the mesh is (especially around the catheter wall), the more accurate the velocity estimations are. In this study, we also utilized this pipeline to qualitatively investigate the effect of catheter presence on the flow field in a truncated right hepatic arterial tree of a liver cancer patient.